INDV
HEALTHCAREIndivior Plc
$40.61+1.02 (+2.58%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving INDV Today?
No stock-specific AI insight has been generated for INDV yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$10.63$41.00
$40.61
Fundamentals
Market Cap$4.8B
P/E Ratio20.8
EPS$1.95
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.2%
Debt / Equity—
Trading
Volume2.8M
Avg Volume (10D)—
Shares Outstanding118.2M
INDV News
22 articles- UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong OutlookYahoo Finance·May 7, 2026
- OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress OutlookYahoo Finance·May 6, 2026
- EDIT's Q1 Loss Narrower Than Expected, Pipeline in FocusYahoo Finance·May 6, 2026
- Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in FocusYahoo Finance·May 5, 2026
- AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity SalesYahoo Finance·May 5, 2026
- Indivior Pharmaceuticals Inc. (INDV) Upgraded to Strong Buy: Here's What You Should KnowYahoo Finance·May 5, 2026
- Indivior Pharmaceuticals Inc. (INDV) is a Great Momentum Stock: Should You Buy?Yahoo Finance·May 5, 2026
- Wall Street Analysts Predict a 27.76% Upside in Indivior Pharmaceuticals Inc. (INDV): Here's What You Should KnowYahoo Finance·May 5, 2026
- Indivior Announces $175 Million Accelerated Share RepurchaseYahoo Finance·May 4, 2026
- Is It Too Late To Consider Indivior Pharmaceuticals (INDV) After A 214% One-Year Surge?Yahoo Finance·May 2, 2026
- Here's Why Momentum in Indivior Pharmaceuticals Inc. (INDV) Should Keep goingYahoo Finance·May 1, 2026
- Indivior PLC Q1 2026 Earnings Call SummaryMoby·May 1, 2026
- AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug MomentumYahoo Finance·Apr 30, 2026
- Amarin's Q1 Loss Narrower Than Expected, Sales Increase Y/YYahoo Finance·Apr 30, 2026
- VKTX Q1 Earnings Miss on Higher Phase 3 Development CostsYahoo Finance·Apr 30, 2026
- Indivior Q1 Earnings Call HighlightsMarketbeat·Apr 30, 2026
- Indivior Pharmaceuticals Inc. (INDV) Q1 Earnings and Revenues Beat EstimatesYahoo Finance·Apr 30, 2026
- Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 GuidanceYahoo Finance·Apr 30, 2026
- NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLAYahoo Finance·Apr 28, 2026
- Indivior Pharmaceuticals Inc. (INDV): Billionaire Howard Marks Trims StakeYahoo Finance·Apr 27, 2026
- Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use DisorderGlobeNewswire Inc.·Apr 24, 2026
- Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30thGlobeNewswire Inc.·Apr 9, 2026
All 22 articles loaded
Price Data
Open$39.19
Previous Close$39.59
Day High$39.90
Day Low$38.76
52 Week High$41.00
52 Week Low$10.63
52-Week Range
$10.63$41.00
$40.61
Fundamentals
Market Cap$4.8B
P/E Ratio20.8
EPS$1.95
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.2%
Debt / Equity—
Trading
Volume2.8M
Avg Volume (10D)—
Shares Outstanding118.2M
About Indivior Plc
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—